ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Development of nomogram based on immune-related gene FGFR4 for advanced non-small cell lung cancer patients with sensitivity to immune checkpoint inhibitors

Wang, Li; Ren, Zhixuan; Yu, Bentong; Tang, Jian*南昌大学; 南方医科大学; 青岛大学; 1
Journal of Translational Medicine2021-1-6DOI: 10.1186/s12967-020-02679-0
12被引7阅读
引用收藏
分享

摘要

Introduction: Immune checkpoint inhibitors (ICIs) have become a frontier in the field of clinical technology for advanced non-small cell lung cancer (NSCLC). Currently, the predictive biomarker of ICIs mainly including the expression of PD-L1, TMB, TIICs, MMR and MSI-H. However, there are no official biomarkers to guide the treatment of ICIs and to determine the prognosis. Therefore, it is essential to explore a systematic nomogram to predict the prognosis of ICIs treatment in NSCLC @@@ Methods: In this work, we obtained gene expression and clinical data of NSCLC patients from the TCGA database. Immune-related genes (IRGs) were downloaded from the ImmPort database. The detailed clinical annotation and response data of 240 advanced NSCLC patients who received ICIs treatment were obtained from the cBioPortal for Cancer Genomics. Kaplan-Meier survival analysis was used to perform survival analyses, and selected clinical variables to develop a novel nomogram. The prognostic significance of FGFR4 was validated by another cohort in cBioPortal for Cancer Genomics. @@@ Results: 3% of the NSCLC patients harbored FGFR4 mutations. The mutation of FGFR4 were confirmed to be associated with PD-L1, and TMB. Patients harbored FGFR4 mutations were found to have a better prolonged progression-free survival (PFS) to ICIs treatment (FGFR4: P = 0.0209). Here, we built and verified a novel nomogram to predict the prognosis of ICIs treatment for NSCLC patients. @@@ Conclusion: Our results showed that FGFR4 could serve as novel biomarkers to predict the prognosis of ICIs treatment of advanced NSCLC. Our systematic prognostic nomogram showed a great potential to predict the prognosis of ICIs for advanced NSCLC patients.

学科与关键词

关键词
NSCLCFGFR4Immune checkpoint inhibitorsImmune-related genesNomogram
相关
加载中…
  • New biomarkers exploration and nomogram construction of prognostic and immune-related adverse events of advanced non-small cell lung cancer patients receiving immune checkpoint inhibitors
    Lin, Xuwen; Chen, Xi; Long, Xiang; Zeng, Chao; Zhang, Zhihan; Fang, Weiyi*; Xu, Ping*Respiratory Research, 2023, 24(1): 64.被引 2
  • ZFHX3 mutation as a protective biomarker for immune checkpoint blockade in non-small cell lung cancer
    Zhang, Jiexia; Zhou, Ningning; Lin, Anqi; Luo, Peng; Chen, Xin; Deng, Huojin; Kang, Shijun; Guo, Linlang*; Zhu, Weiliang*; Zhang, JianCancer Immunology, Immunotherapy, 2021, 70(1): 137-151.被引 60
  • TNF-Alpha Pathway Alternation Predicts Survival of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
    Lin, Anqi; Zhang, Hongman; Meng, Hui; Deng, Ze; Gu, Tianqi; Luo, Peng*; Zhang, Jian*Frontiers in Immunology, 2021, 12: 667875.被引 8
查看全部 →

发表信息

论文状态
公开发表
期刊
Journal of Translational Medicine
发表日期
2021-01-06
卷期
第 19 卷, 第 1 期
页码
22
DOI
10.1186/s12967-020-02679-0
语言
ENGLISH
期刊收录
NSL
期刊等级
2区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [81360019, 81860025]

作者

  • W

    Wang, Li (第一作者)

    qingdao univ

  • R

    Ren, Zhixuan

    southern med univ

查看全部 4 位作者收起作者
  • Y

    Yu, Bentong

    1 · nanchang univ

  • T

    Tang, Jian (通讯)

    1 · nanchang univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417